Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > BUSINESS
BUSINESS
- Illumina Eyes Japan Launch of Comprehensive Genomic Profiling Test This Year
March 16, 2023
- Paxlovid to Enter Normal Distribution from March 22: Pfizer Japan
March 16, 2023
- Ono, PeptiDream in Deal for Macrocyclic Constrained Peptide Therapeutics
March 16, 2023
- Iron Solution MonoVer Now Available in Japan; Donepezil Patch, Cresemba to Hit Market in April
March 16, 2023
- Teijin Pharma Plans Pivot to Rare Diseases as Generics Eat into Feburic Sales
March 15, 2023
- Xtandi Hits Mark in China HSPC Study to Pave Way for Label Expansion
March 15, 2023
- Takeda’s Dengue Vaccine Approved in Brazil
March 15, 2023
- Eisai’s Leqembi Wins Coverage from US Veteran’s Body
March 15, 2023
- Bayer Setting Out to Cut Up to 480 Jobs as Xarelto Patent Cliff Looms: Employee
March 14, 2023
- Japan’s Non-COVID Jab Market to Surpass 180 Billion Yen by 2030: Fuji Keizai
March 14, 2023
- Moderna, Tohoku University Link Up for Next-Gen Healthcare
March 14, 2023
- Shionogi Inks Malaria Drug Collab with Nagasaki University, MMV
March 14, 2023
- Serious Side Effect Cases Total 8: Xocova Safety Update
March 13, 2023
- Padcev Application Accepted for Review in China: Astellas
March 13, 2023
- AstraZeneca Looks to 1st IO/ADC Launch as Leader in the Race: Oncology Head
March 13, 2023
- Eisai Eyes 1 Trillion Yen in Leqembi Global Sales in FY2030: CEO
March 10, 2023
- Xospata Fails in PIII for Post-Transplant AML Maintenance Therapy: Astellas
March 10, 2023
- Shingo Iwamoto Sworn in as New Chief of Nichi-Iko; Tamura Bows Out
March 9, 2023
- Silgard 9 Approved for 2-Dose Schedule: MSD
March 9, 2023
- Nipro Curbed Shipments of 28 APIs/40 Products as Precaution for Rush Demand
March 9, 2023
ページ
Japan’s pharmaceutical industry is undergoing a structural shift in its workforce, with the role of sales reps shrinking while production…
In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…